Carley D W, Trbovic S M, Radulovacki M
Department of Pharmacology, College of Medicine, University of Illinois at Chicago 60612, USA.
Sleep. 1996 Jun;19(5):363-6. doi: 10.1093/sleep/19.5.363.
The effects of lowering blood pressure (BP) by hydralazine (HY) (2 mg/kg) on spontaneous (SA) and post-sigh (PSA) sleep apneas have been studied in spontaneously hypertensive (SHR) rats by monitoring their respiration and sleep by the EEG for 6 hours. Normotensive Wistar-Kyoto (WKY) rats, from which the SHR rat strain was derived, were used as an appropriate control. The SHR rats had more SA (p < 0.02) and PSA (p < 0.0001) apneas/hour than WKY rats during nonrapid eye movement sleep and their mean BP was higher by 40 mm Hg (p < 0.0001) than WKY rats. Administration of HY to SHR rats equalized their BP with the arterial pressure of WKY rats and reduced the SA and the PSA apneas/hour to equivalence with WKY normotensive rats. These results demonstrate that even in the context of lifelong hypertension, acute normalization of BP significantly reduces sleep apneas in rats. They further suggest that improved management of BP may be clinical benefit to patients with apnea who have long-standing hypertension.
通过监测自发性高血压（SHR）大鼠的呼吸和脑电图睡眠6小时，研究了肼屈嗪（HY，2mg/kg）降低血压（BP）对自发性（SA）和叹息后（PSA）睡眠呼吸暂停的影响。作为合适的对照，使用了培育出SHR大鼠品系的正常血压Wistar-Kyoto（WKY）大鼠。在非快速眼动睡眠期间，SHR大鼠每小时的SA（p<0.02）和PSA（p<0.0001）呼吸暂停次数比WKY大鼠更多，且其平均血压比WKY大鼠高40mmHg（p<0.0001）。给SHR大鼠施用HY可使其血压与WKY大鼠的动脉压相等，并将每小时的SA和PSA呼吸暂停次数降低至与WKY正常血压大鼠相当的水平。这些结果表明，即使在终身高血压的情况下，血压的急性正常化也能显著减少大鼠的睡眠呼吸暂停。它们进一步表明，改善血压管理可能对患有长期高血压的呼吸暂停患者具有临床益处。
